1. Introduction {#sec1-jcdd-04-00012}
===============

Cardiomyopathies are a heterogenous group of diseases directly affecting the myocardial tissue composing a remarkable percentage of heart failure (HF) cases. Dilated cardiomyopathy (DCM) is defined by the presence of ventricular chambers dilatation and contractile dysfunction leading to heart failure (HF) \[[@B1-jcdd-04-00012]\]. Thus, rather than a single nosographic entity, DCM can be conceived as a morpho-functional phenotype representing the end stage of common pathways possibly deriving from a range of diverse underlying causes (infectious, metabolic, inflammatory, toxic, genetic) \[[@B2-jcdd-04-00012]\]. If an etiology is not deemed despite a careful clinical evaluation and instrumental diagnostic work-up, DCM is considered as idiopathic DCM (iDCM).

Among HF cases, subjects presenting with iDCM are at least 10 years younger than other etiologic cohorts (ischemic, hypertensive, and valvular) and more critically ill (75% in NYHA class III-IV). They carry a mortality rate comparable to valvular disease (≈65% at 5 years) that is only inferior to ischemic cardiomyopathy with reduced ejection fraction \[[@B3-jcdd-04-00012]\]. In this context, non-pharmacological approaches such as electrical device implants \[[@B4-jcdd-04-00012]\], mechanical circulatory supports \[[@B5-jcdd-04-00012],[@B6-jcdd-04-00012]\], surgical corrections \[[@B7-jcdd-04-00012]\], and stem cell based therapies \[[@B8-jcdd-04-00012]\] have found space showing different degrees of feasibility and efficacy on long-term survival and life-quality improvement. Nevertheless, the current pharmacological mainstay for iDCM does not significantly differ from the general HF population in light of the frequent inclusion of such a subgroup in large clinical trials \[[@B9-jcdd-04-00012]\].

The recognition of this paradox may require consideration of iDCM as an independent single entity, as well as the revaluation of the role of drugs that are not employed as first-line therapy in iDCM. This backward approach allows us to resurrect interest in neglected drugs and, through an inductive reasoning, to reach a deeper understanding of iDCM abnormalities and pathophysiological mechanisms.

2. Methods {#sec2-jcdd-04-00012}
==========

We searched the Pubmed Library (last access 1 June 2017) for articles published between 1985 and 2016 in English with full text available and reference lists of related papers. Terms employed in the query were "idiopathic dilated cardiomyopathy" and "clinical trial", either alone or together in different combinations. Only post-hoc analysis and placebo-controlled studies were included, as well as those where the term dilated was mentioned within the text as the phenotype of either a percentage or the total population study. Exclusion criteria were: pediatric patients, device and/or stem cell based therapies, pheresis and intracoronary infusions, and acute drug effect evaluation without follow-up. In addition, in the case of the mentioned primary cause of myocardial dysfunction and organ dilatation (viral myocarditis, alcohol or drug abuse, etc.) studies were not included, as these cases can be successfully treated by exposure cessation or targeted therapies.

In light of the diverse classes of drugs, clinical heterogeneity and different methods of data reporting, a meta-analysis was unfeasible. A meta-analysis was unfeasible for several reasons: different drug classes, diverse therapeutic mainstays (pre-β blocker and β blocker eras), clinical heterogeneity (from suboptimal to severely impaired left ventricle ejection fraction), different methods of data reporting, and the unavailability of single patient data. Nevertheless, statistical significance for changes upon treatment for molecular results, morphofunctional parameters, and clinical endpoints were reported for every study. We reported descriptive statistics with charts and graphs with Microsoft Office Excel for MacOS X.

3. Results {#sec3-jcdd-04-00012}
==========

3.1. General Study Characteristics {#sec3dot1-jcdd-04-00012}
----------------------------------

The query identified 33 studies published within our selected timeframe.

[Figure 1](#jcdd-04-00012-f001){ref-type="fig"} illustrates the distribution of size, design and follow-up length of the analyzed clinical studies \[[@B10-jcdd-04-00012],[@B11-jcdd-04-00012],[@B12-jcdd-04-00012],[@B13-jcdd-04-00012],[@B14-jcdd-04-00012],[@B15-jcdd-04-00012],[@B16-jcdd-04-00012],[@B17-jcdd-04-00012],[@B18-jcdd-04-00012],[@B19-jcdd-04-00012],[@B20-jcdd-04-00012],[@B21-jcdd-04-00012],[@B22-jcdd-04-00012],[@B23-jcdd-04-00012],[@B24-jcdd-04-00012],[@B25-jcdd-04-00012],[@B26-jcdd-04-00012],[@B27-jcdd-04-00012],[@B28-jcdd-04-00012],[@B29-jcdd-04-00012],[@B30-jcdd-04-00012],[@B31-jcdd-04-00012],[@B32-jcdd-04-00012],[@B33-jcdd-04-00012],[@B34-jcdd-04-00012],[@B35-jcdd-04-00012],[@B36-jcdd-04-00012],[@B37-jcdd-04-00012],[@B38-jcdd-04-00012],[@B39-jcdd-04-00012],[@B40-jcdd-04-00012],[@B41-jcdd-04-00012],[@B42-jcdd-04-00012]\].

Three studies were not included as we considered only the completed, the largest, and the most comprehensive dataset of a study to our knowledge in spite of respective ongoing reports.

As shown in [Figure 2](#jcdd-04-00012-f002){ref-type="fig"}, among 3392 patients and at least 2527 subjects (74.5%) were classified as iDCM or non-ischemic DCM. Only 8 studies (24%) recruited more than 100 patients, and 5 (15%) had a mean follow-up duration longer than 12 months. These characteristics could have negatively affected the accomplishment of a robust statistical significance and a hard end-point. When reported, the highest LVEF threshold was 47% for patient recruitment; nevertheless, the average LVEF was variable among the studies (ranging from 18% to 40%). Possible ischemic etiology was assessed either by scintigraphic, angiographic, or electrocardiographic methods, functional tests (6 min walking test), a clinical presentation, or anamnestic evaluation. [Table 1](#jcdd-04-00012-t001){ref-type="table"} shows the individual study characteristics.

3.2. Overall Findings {#sec3dot2-jcdd-04-00012}
---------------------

Heatmap in [Figure 3](#jcdd-04-00012-f003){ref-type="fig"} offers a general overview of the overall findings among selected studies.

The drug effect on biomarkers revealed a general positive trend of inflammation resolution for several classes (statins, pentoxifylline, PUFAs): TNFα plasma concentration showed up to a threefold decrease with treatment \[[@B18-jcdd-04-00012]\]. In contrast, thalidomide increased its concentration. NT-proBNP levels decreased in the aforementioned drug classes too \[[@B10-jcdd-04-00012],[@B12-jcdd-04-00012],[@B16-jcdd-04-00012],[@B17-jcdd-04-00012],[@B30-jcdd-04-00012],[@B32-jcdd-04-00012]\].

Echocardiographic assessment revealed a substantial or even significant benefit for LVEF in the verum cohorts with the exception of perhexelline and corticosteroids. However, data were uncomparable among groups in light of the various available pharmacologic treatments at different timepoints (pre-β-blocker and β-blocker era). Notably, LVEF improvement was more frequently associated with LV end-systolic dimension reductions rather than the end-diastolic, suggesting a more distinct role on contractility instead of sole remodeling. Functional improvement (either assessed by a 6 min-walking test or an NYHA class) was detected in the majority of the studies, particularly in medications related to energetics improvement (CoQ10).

Thirteen studies (39%) reported results on hard clinical end-points, such as hospitalization rates and cardiovascular or overall mortalities. This low response rate reflects a series of factors: a short mean follow-up, low prescription prevalence, drug costs, and the heterogenous clinical status of patients recruited in different trials. Patients treated with statins had significantly higher survival rates (≈75% vs. 40% at 5-year follow-up *p* \< 0.01) and the largest study analyzed proved a significant protection despite a lack of ischemic etiology (Adjusted CV Mortality HR = 0.42, 95% 0.18--0.95 *p* \< 0.04). Steroids and thalidomide showed a reduced, yet non-significant, survival rate. Not surprisingly, long PDEi treatments were associated with higher mortality rates. Of note, the benefit (survival rate) occurring at the earliest timepoint (2 months) was found for treatment with the natural plant extract Berberine (91% vs. 86% *p* \< 0.01).

4. Discussion {#sec4-jcdd-04-00012}
=============

Positive and negative results collected from different clinical trials allowed us to reevaluate current treatments and highlight specific molecular pathways in the management of HF. This specular approach, in opposition to the traditional drug development pipeline, provides evidence-based insights and immediate interpretation.

As postulated by Chien nearly 20 years ago, dilated cardiomyopathy relies on four biological components which are intimately linked to each other (biomechanical stimuli, cytoskeletal signaling, myocyte survival, and calcium cycling) \[[@B43-jcdd-04-00012]\]. Since a remarkable body of literature on iDCM has grown in recent years, we can revisit such a biological equation.

4.1. Not All Statins Were Created Equal {#sec4dot1-jcdd-04-00012}
---------------------------------------

Being commonly prescribed, studies on statins provide the most robust dataset. Statins differ among each other for several pharmacokinetics criteria, and lipophilicity is a critical determinant. Lipophilic statins (Atorvastin, Simvastatin, i.e.,) can passively diffuse the membrane of extrahepatic cells. This ability supports the findings by Tsutamoto who demonstrated a superior clinical improvement in DCM patients with Atorvastatin compared to a hydrophilic one (Rosuvastatin) \[[@B44-jcdd-04-00012]\]. Statins, along with their well-known lipid-lowering effect, have pleiotropic effects due to the inhibition of 3-hydroxy-3methyl-glutaryl-coenzyme A (HMG-CoA) reductase. Such blockade decreases mevalonate synthesis and, ultimately, farnesylpyrophosphate biosynthesis, a critical biochemical crossroad shared by G-protein Rho and its numerous related subfamily members (Rac, ROCK, Ras), as described by Oesterle \[[@B45-jcdd-04-00012]\]. Rho downstream effectors lead to cell proliferation, differentiation, and cytoskeletal changes directly affecting cell geometry, integrity, adhesion, and stability \[[@B46-jcdd-04-00012],[@B47-jcdd-04-00012],[@B48-jcdd-04-00012]\]. In addition, statins can relieve inflammatory signaling by modulating Rac1 and peroxisome proliferator activated receptors (PPARs), which in turn decrease ROS and NADPH oxidase activity and TNF-α concentrations respectively \[[@B49-jcdd-04-00012],[@B50-jcdd-04-00012]\].

4.2. Inflammation Resolution: Is It Worth? {#sec4dot2-jcdd-04-00012}
------------------------------------------

As anticipated, systemic, and local inflammation have been viewed as pivotal components of myocardial dysfunction. In the past a plethora of putative inflammatory mediators has been evaluated. Among them, TNFα is recognized as a major effector of myocardial damage and considered as a reliable HF biomarker for a number of reasons \[[@B51-jcdd-04-00012],[@B52-jcdd-04-00012],[@B53-jcdd-04-00012],[@B54-jcdd-04-00012],[@B55-jcdd-04-00012],[@B56-jcdd-04-00012]\]. In addition to the reported increase in tissue and plasma TNFα concentration in patients with HF and iDCM, cardiac-specific transgenic mice overexpressing TNFα recapitulated the human pathophysiology of DCM with four-chamber dilatation, myocyte hypertrophy, increased fibrosis, diminished β-adrenergic responsiveness, and premature death \[[@B57-jcdd-04-00012]\]. These findings composed a solid biological rationale to target TNFα and were sufficient and appropriate to justify the clinical sperimentation of a monoclonal antibody or a decoy receptor (infliximab and etanercept). Nevertheless, the complete biological abrogation of this cytokine did not lead to any significant clinical benefit, suggesting additional underestimated compensatory effects by TNFα and a more complex biological role in HF pathophysiology \[[@B58-jcdd-04-00012],[@B59-jcdd-04-00012],[@B60-jcdd-04-00012]\].

Antinflammatory therapies such as thalidomide have had minimal clinical application in iDCM management and steroideal drugs are advisable only to resolve viral driven damage in the setting of positive myocardial lymphocytic infilitration or HLA hyperexpression \[[@B61-jcdd-04-00012]\]. In contrast, a xantine derivative (namely pentoxifylline) was employed in four different trials for a total of 151 randomized iDCM subjects for antagonizing TNFα. Results were promising for reducing apoptotic stimuli and inflammatory biomarkers \[[@B20-jcdd-04-00012]\], translating into a clinical improvement, but were still insufficient to grant its use in the general DCM population, although worthy for starting a larger clinical trial. These outcomes cannot be simply linked to the inflammatory resolution; in fact, pentoxifyilline has a positive inotropic and vasodilatatory activity above the other effects. This aspect is not marginal, especially in the DCM setting.

4.3. Inotropism Manipulation: A Double-Edged Knife {#sec4dot3-jcdd-04-00012}
--------------------------------------------------

Inotropic agents are engulfed together in light of their positive effect on myocardial contractility. Their various mechanisms of action are extensively described elsewhere \[[@B62-jcdd-04-00012],[@B63-jcdd-04-00012]\]. In the race for HF management, such agents have gained momentum in the past, despite not meeting the expectations they generated during their introduction. Among them, the "calcium mobilizers" class is a heterogenous group of drugs that modulate calcium dynamics through different mechanisms with degrees of specificity for molecular targets ultimately leading to contractile improvements \[[@B64-jcdd-04-00012]\]. Over the last three decades, several of these drugs have been developed, but only few have found a clinical application, especially in the setting of acute HF. In fact, an intracellular calcium overload is detrimental for functional and survival reasons exceeding the advantages on the contractile apparatus. This double-edged knife effect applies to the decompensated heart too where calcium overload cannot be handled properly by the calcium handling proteins \[[@B65-jcdd-04-00012],[@B66-jcdd-04-00012],[@B67-jcdd-04-00012]\]. In the setting of ischemic cardiomyopathy, an insufficient blood supply does not allow a proper ATP availability to sustain ATP-dependent calcium handling pumps, justifying the use of this inotropic mean in the unlikely case of first-line therapies' unresponsiveness (diuretics). Interestingly, Dec reported the significant difference between the idiopathic dilated phenotype and ischemic etiology in patients receiving oral enoximone: only 5% of ischemic patients were alive at 18 months follow-up versus 66% of DCM \[[@B68-jcdd-04-00012]\]. This is a dramatic divergence between the DCM subgroup and the general HF population in terms of clinical long-term endpoint. It thus appears as a valid reason to reconsider cardiac inotropes for medium-termed treatments and for this specific subgroup, in spite of their general contemporary minimal employment.

4.4. Mitochondrion: A Hijacked Powerhouse {#sec4dot4-jcdd-04-00012}
-----------------------------------------

In this scenario, cardiac energetics must be also considered, as both contraction and relaxation heavily rely on ATP availability. It is now broadly accepted that mitochondria are involved in a wide range of diseases, including HF \[[@B69-jcdd-04-00012]\]. Of note, among nearly 40 target genes associated with DCM \[[@B70-jcdd-04-00012]\], TAZ (tafazzin) is enlisted too and it encodes for a component of the mitochondrial inner membrane \[[@B71-jcdd-04-00012]\]. The myocardial metabolism of iDCM is severely impaired, with energetic starvation, and is characterized both at transcriptional and functional levels by free fatty acid (FFA) metabolism reduction and glucose metabolism induction, whose use is energetically more efficient \[[@B72-jcdd-04-00012],[@B73-jcdd-04-00012]\]. Interestingly, insulin resistance is a relatively common comorbidity in iDCM patients and it might suggest an interference in glucose uptake too \[[@B74-jcdd-04-00012]\]. Whether HF precedes metabolic alterations or vice versa remains a "chicken or egg" dilemma. Starting from this paradox, a series of clinical trials was started and here reported. Coenzyme Q10 and [l]{.smallcaps}-carnitine represent two valid dietary supplementations that could have a therapeutic role by enhancing mitochondrial activity either by favoring the electron transport chain between complex II and III or increasing FFA as a substrate, respectively. The former has been extensively described in a recent review \[[@B75-jcdd-04-00012]\], and in our review only the NYHA functional class appeared to significantly improve. Instead, [l]{.smallcaps}-carnitine was found to significantly decrease the overall mortality in iDCM patients (3% vs. 18% at 3 year follow-up). Ironically, trimetazidine, whose mechanism of action is FFA oxidation blockade, was found to be beneficial on cardiac function and clinical symptoms in shorter observation times too. Perhexelline, which is conceptually opposite to [l]{.smallcaps}-carnitine, improved the NYHA class too. All in all, such findings should be confirmed and implemented with future, larger, and longer studies. Nevertheless, reported trivial findings from conceptually different rationales still question whether these metabolic alterations are putative pathologic mechanisms to be tackled or compensatory ones to be enhanced.

4.5. Growth Hormone: New Bricks for a Crumbling Heart? {#sec4dot5-jcdd-04-00012}
------------------------------------------------------

Finally, a component of DCM progression included in the above mentioned equation is myocyte apoptosis. It is widely accepted that cell loss is a critical determinant of HF \[[@B76-jcdd-04-00012],[@B77-jcdd-04-00012]\]. Over time, a net depletion of the myocyte count contributes to the cardiac dysfunction generally observed with aging or in certain cardiomyopathies. As reported by Pluess, iDCM hearts show high variability in cell size, as well as prominent fibrous deposition affecting the 3D structure leading to abnormal cell-to-cell contact. Such architectural changes constitute a proarrhythmogenic anatomical substrate and bring the cell unit to a sub-optimal mechanical coordination with neighbouring cells \[[@B78-jcdd-04-00012]\]. Independently from the magnitude of these events, growth hormone (GH) represents a valid and applealing option to counteract such defects by suppressing apoptosis and favoring cell proliferation \[[@B79-jcdd-04-00012]\]. In 1996, a non-placebo-controlled clinical study demonstrated remarkable improvements in systolic and diastolic function (LVEF increase, LV end diastolic and systolic dimension reduction, E/A ratio improvement) over a 3 month treatment \[[@B80-jcdd-04-00012]\]. These results were not met by subsequent clinical placebo-controlled studies, leaving many unanswered questions concerning its use as drug cost-effectiveness, the administration method (continuous vs. pulsitile), treatment duration (\>6 months), and possible colonic neoplastic evolution \[[@B81-jcdd-04-00012]\]. If GH is recommendable in case of deficiency \[[@B82-jcdd-04-00012]\], its use in iDCM remains a matter or investigation and evaluation in light, also, of a small clinical study with positive results testing the cardiovascular effect of octreotide \[[@B83-jcdd-04-00012]\], a somatostatin analog \[[@B84-jcdd-04-00012]\].

4.6. A Challenging Equation {#sec4dot6-jcdd-04-00012}
---------------------------

Cell stability, inflammatory status, metabolic depletion, mechanical modulation, calcium dynamics, and cell survival compose a tangled interplay of factors intimately linked with each other in the determinism of iDCM development and progression. Moreover, as anticipated, several drugs reported in this study have pleiotropic and overlapping effects over a series of molecular and cell targets. In order to update this equation, [Figure 4](#jcdd-04-00012-f004){ref-type="fig"} was conceived to better summarize the results that emerged from the present work and to help future researchers and physicians to solve this jigsaw.

5. Conclusions {#sec5-jcdd-04-00012}
==============

In conclusion, the present study highlights putative therapeutic targets that can be employed for the treatment of iDCM based on previous clinical trials. This goal can be reached through several efforts. As adviced by Bierer, data authorship policies can be a future incentive for data sharing by promoting the generation of a larger database merging past clinical studies' results \[[@B85-jcdd-04-00012]\]. In addition, future studies are encouraged to be multricentric and multimodal in light of the specific phenotype of iDCM and the urge to assess drug effectiveness at cell, tissue, and whole organ levels. Furthermore, in the era of precision medicine, the use of new algorithms based on novel prognostic biomarkers will help clinicians to tailor the most suitable therapy for such a heterogenous population. Lastly, the identification of molecular targets can lead to drug repurposing and the development of new ones in the near future. By adopting these solutions, medicine will replenish its pharmacological armamentarium in the war against heart failure \[[@B86-jcdd-04-00012]\].

6. Limitations {#sec6-jcdd-04-00012}
==============

Limitations of the present study are as follows. The search criteria are stringent in order to be specific for the idiopathic DCM phenotype, and therefore a number of studies were not included because of heterogenous nomenclature. The use of non-ischemic cardiomyopathy wording allows for the exclusion of coronaropathies, but does not distinguish between other etiologies (hypertensive, valvular, inflammatory, toxic, and idiopathic). The pediatric population was not included in the current study as this peculiar subgroup is generally separated from the adult population of clinical trials. The report of statistical significance does not provide any information regarding the magnitude of benefit or the damage derived from treatment.
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![Bar graph showing the total number of recruited patients per drug class. Of note, the unspecified and non-iDCM groups represent heterogeneous population composed of ischemic, valvular, hypertensive, peripartum, post viral myocarditis cardiomyopathy, and an undisclosed number of iDCM subjects.](jcdd-04-00012-g002){#jcdd-04-00012-f002}

![Heatmap reporting statistical significance of molecular results, morphofunctional parameters, and clinical endopoints in 33 clinical studies. Abbreviations---(OM KM) overall mortality Kaplan-Meier, (OM HR) overall mortality Hazard Ratio, (CVM KM) cardiovascular mortality Kaplan-Meier, (CVM HR) cardiovascular mortality Hazard Ratio, (Hosp) hospitalization, (NYHA) NYHA functional class, (6MWT) 6-min walking test, (LVEF) left ventricle ejection fraction, (LVEDDV) left ventricle end-diastolic dimension/volume, (LVESDV) left ventricle end-systolic dimension/volume, (Mass) Cardiac Mass, (MV E/A) Mitral valve E/A ratio, (VO2 Max), maximum oxygen uptake, (W Stress) wall stress.](jcdd-04-00012-g003){#jcdd-04-00012-f003}

![Summary of pleiotropic and overlapping effects of drug classes towards putative pathologic driving mechanisms of iDCM.](jcdd-04-00012-g004){#jcdd-04-00012-f004}

jcdd-04-00012-t001_Table 1

###### 

Clinical studies targeted for dilated cardiomyopathy pharmacological management.

  Author                                        Year   No. of Patients iDCM/Total (%)   Study Type and Design   Active Drug Target                    Follow-up (Months)   LVEF %   
  --------------------------------------------- ------ -------------------------------- ----------------------- ------------------------------------- -------------------- -------- -----
  **Statins**                                                                                                                                                                       
  Node K \[[@B10-jcdd-04-00012]\]               2003   48/48 (100%)                     Double blind            Simvastatin (10 mg/day)               3                    40       34
  Laufs U \[[@B11-jcdd-04-00012]\]              2004   15/15 (100%)                     Double blind            Cerivastatin (0.4 mg/day)             5                    n/a      40
  Bleske BE \[[@B12-jcdd-04-00012]\]            2006   15/15 (100%)                     Crossed                 Atorvastatin (80 mg/day)              3                    45       25
  Goldberger JJ \[[@B13-jcdd-04-00012]\]        2006   458/458 (100%)                   Post hoc analysis       Any statin at any dosage              24                   35       20
  Domanski M \[[@B14-jcdd-04-00012]\]           2007   1024/1024 (100%)                 Post hoc analysis       Any statin at any dosage              24                   35       25
  Liu M \[[@B15-jcdd-04-00012]\]                2009   64/64 (100%)                     Double blind            Atorvastatin (10mg/day)               3                    40       35
  Bielecka-Dabrowa A \[[@B16-jcdd-04-00012]\]   2013   68/68 (100%)                     Open                    Atorvastatin (10 or 20 mg/day)        60                   n/a      32
  Broch K \[[@B17-jcdd-04-00012]\]              2014   71 unspecified                   Double blind            Rosuvastatin (10 mg/day)              6                    40       36
  **Pentoxifylline**                                                                                                                                                                
  Sliwa K \[[@B18-jcdd-04-00012]\]              1998   28/28 (100%)                     Double blind            Pentoxifylline (400 mg/tid)           6                    40       22
  Skudicky D \[[@B19-jcdd-04-00012]\]           2001   39/39 (100%)                     Double blind            Pentoxifylline (400 mg/tid)           6                    40       24
  Sliwa K \[[@B20-jcdd-04-00012]\]              2002   18/18 (100%)                     Double blind            Pentoxifylline (400 mg/tid)           1                    40       16
  Bahrmann P \[[@B21-jcdd-04-00012]\]           2004   17/47 (36.2%)                    Double blind            Pentoxifylline (600 mg/bid)           6                    40       29
  **Inotropes**                                                                                                                                                                     
  Uretsky BF \[[@B22-jcdd-04-00012]\]           1990   102 unspecified                  Double blind            Enoximone (100 or 150 mg/tid)         4                    n/a      22
  Feldman AM \[[@B23-jcdd-04-00012]\]           1991   38/76 (50%)                      Double blind            Vesnarinone (60 mg/day)               3                    n/a      24
  Katz SD \[[@B24-jcdd-04-00012]\]              1992   14/49 (28.6%)                    Double blind            Pimobendan (5 or 10 mg/day)           3                    n/a      19
  Cowley AJ \[[@B25-jcdd-04-00012]\]            1994   26/151 (16.6%)                   Double blind            Enoximone (50 or 100 mg/tid)          12                   n/a      n/a
  **Growth Hormone (GH)**                                                                                                                                                           
  Osterziel KJ \[[@B26-jcdd-04-00012]\]         1998   50/50 (100%)                     Double blind            rhGH subq (2 IU/qd)                   3                    45       26
  Isgaard J \[[@B27-jcdd-04-00012]\]            1998   13/22 (59.1%)                    Double blind            rhGH subq (to 4 IU/qd)                3                    45       30
  Fazio S \[[@B28-jcdd-04-00012]\]              2007   13/22 (59.1%)                    Double blind            rhGH subq (to 4 IU/qod)               3                    40       32
  **Trimetazidine**                                                                                                                                                                 
  Tuunanen H \[[@B29-jcdd-04-00012]\]           2008   19/19 (100%)                     Single blind            Trimetazidine (35 mg/bid)             3                    47       31
  Zhao P \[[@B30-jcdd-04-00012]\]               2013   80/80 (100%)                     Double blind            Trimetazidine(20mg/tid)               6                    40       34
  **Polyunsaturated Fatty Acids (PUFAs)**                                                                                                                                           
  Nodari S \[[@B31-jcdd-04-00012]\]             2011   133/133 (100%)                   Double blind            EPA/DHA850 mg/bid                     12                   45       36
  Chrysohoou C \[[@B32-jcdd-04-00012]\]         2016   205 unspecified                  Open                    PUFA 1000 mg/day                      6                    40       28
  **CoQ10**                                                                                                                                                                         
  Watson PS \[[@B33-jcdd-04-00012]\]            1999   23/30 (76.7%)                    Cross                   CoQ10 (33 mg/tid)                     3                    35       26
  Keogh A \[[@B34-jcdd-04-00012]\]              2003   39 unspecified                   Double blind            CoQ10 (150 mg/day)                    3                    40       n/a
  **Herbal Medications**                                                                                                                                                            
  Bharani A \[[@B35-jcdd-04-00012]\]            1995   10/12 (83.3%)                    Cross                   *Terminalia Arjuna* (500 mg/tid)      0.5                  n/a      30
  Zeng XH \[[@B36-jcdd-04-00012]\]              2003   62/156 (39.8%)                   Double blind            Berberine (up to 0.5 g/qid)           2                    n/a      22
  **L-carnitine**                                                                                                                                                                   
  Rizos I \[[@B37-jcdd-04-00012]\]              2000   80/80 (100%)                     Open                    L-carnitine (2 g/day)                 34                   n/a      27
  **Levotyroxine (T4)**                                                                                                                                                             
  Moruzzi P \[[@B38-jcdd-04-00012]\]            1996   20/20 (100%)                     n/a                     Levotyroxine (100 ug/day)             3                    40       30
  **Ivabradine**                                                                                                                                                                    
  Abdel-Salam Z \[[@B39-jcdd-04-00012]\]        2015   43/43 (100%)                     Double blind            Ivabradine(2.5 mg/tid)                3                    40       34
  **Thalidomide**                                                                                                                                                                   
  Gullestad L \[[@B40-jcdd-04-00012]\]          2005   17/56 (30.4%)                    Double blind            Thalidomide (200 mg/qd)               3                    40       24
  **Steroids**                                                                                                                                                                      
  Parrillo JE \[[@B41-jcdd-04-00012]\]          1989   42/102 (41.2%)                   Open                    Prednisone (60 mg/day) for 3 months   15                   35       18
  **Perhexelline**                                                                                                                                                                  
  Beadle RM \[[@B42-jcdd-04-00012]\]            2015   50/50 (100%)                     Double blind            Perhexelline (200 mg/day)             2                    40       27
